Great, so Glück needs to get on the phone and sell Regeneron or Celgene on Leronlimab. That's his job now. Pfizer is trying to take over NASH, they presented, then withdrew, Ervogastat/Clesacostat Combination for NASH at the last conference. Our job is to convince them that LL is the answer.